Seizures, paroxysmal neurological symptoms caused by episodic and pathologic neuronal discharging, have myriad associated signs/ symptoms that are dependent upon its anatomical origin and subsequent spread. The underlying causes of "epilepsy" (recurrent seizures) are many and include genetic factors, congenital and/or developmental anomalies, infections, trauma, and tumors. The incidence of epilepsy is approximately 1 %. While antiepileptic drugs (AEDs) can frequently control seizures, 30-40 % of patients fail to achieve control. Various approaches exist for those who fail AED treatment. A surgical approach is important because properly selected patients may be amenable to an excisional operation and possible "cure." Dietary manipulations, e.g., the ketogenic diet or the modified Atkin's diet, are often helpful but rarely curative. Brain-stimulation techniques are available for the refractory patient. These techniques include the vagal nerve stimulator (VNS), the responsive neural stimulator (RNS), and transcranial magnetic stimulation (TMS).
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Vagal Nerve Stimulator
VNS has the longest history of the three modalities. After more than 10 years in development, the US Food and Drug Administration (FDA) approved it in 1997 for patients over 12 years old with medically refractory partial epilepsy. 1 Shortly thereafter the American Academy of Neurology (AAN) issued an advisory stating that patients should undergo evaluations at an epilepsy center to determine the etiology and assess candidacy for excisional surgery. Later, the AAN updated its guidelines to include children with refractory partial or generalized epilepsy who are not surgical candidates. 2 The VNS is placed in a subcutaneous surgical pocket under the left clavicle and attached to wire leads that are wrapped around the left vagus nerve.
The device is tested in the operating room for functionality and patients return in 1 to 2 weeks to have it activated. Thereafter, they return frequently for adjustments to the stimulating parameters. This is performed through an external wand attached to a computer. While the ultimate stimulating parameters are not clearly defined, they are adjusted as tolerated and according to clinical responses. Stimulations are programmed to occur at regular intervals and the patient can activate the VNS to deliver additional stimulation by swiping a magnet over the device. This is helpful in those patients who have clear auras.
Response rates vary from >30 to 65 % in clinical trials. Early on, it appeared that response rates seemed to increase between the first and third year of use. Responses vary relative to the type of underlying seizure disorder with idiopathic generalized epilepsy being perhaps the most responsive. 
